¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Carcinoma, Ehrlich Tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® thyroid carcinoma ÇÑ±Û °©»ó»ù¾ÏÁ¾
¼³¸í   
  °©»ó»ù¿¡ »ý±ä »óÇǼ¼Æ÷·Î ÀÌ·ç¾îÁø ¾Ç¼ºÁ¾¾ç¹°. º´¸®Á¶Á÷ÇÐÀûÀΠÇüÅ¿¡ µû¶ó À¯µÎ»ó, ¼ÒÆ÷»ó, ¿ªÇü¾ÏÁ¾ ¹× ¼öÁú¾ÏÁ¾, ¸²ÇÁÁ¾ µîÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖÀ¸³ª, ÀϺο¡¼­´Â ¹æ»ç¼±Æø·Î¿¡ ÀÇÇØ ¹ß»ýÇÑ´Ù. Ä¡·á´Â ¼ö¼ú, ¹æ»ç¼º ¿Á¼Ò, T4 ¾ïÁ¦¿ä¹ý µîÀÌ »ç¿ëµÈ´Ù.
¿µ¹® bronchogenic carcinoma ÇÑ±Û ±â°üÁö¿ø¼º ¾ÏÁ¾
¼³¸í   
  ÆóÀÇ ±â°üÁö ¼¼Æ÷¿¡¼­ ±â¿øÇϴ Á¾¾ç. Æó¾ÏÀÇ Á¾·ù¿¡¼­ °¡Àå ÈçÇÑ ÇüÅÂ(90%ÀÌ»ó)ÀÌ´Ù. Çö¹Ì°æÀû ¼Ò°ß¿¡ µû¶ó »ù¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾, ¼Ò¼¼Æ÷(ÀÛÀº¼¼Æ÷) ¾ÏÁ¾ÀÇ 4°¡Áö·Î ³ª´«´Ù. ÀÌÁß¿¡¼­ ÆíÆò¼¼Æ÷¾ÏÁ¾ÀÌ °¡Àå ÈçÇÑ ÇüÅÂÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(non-small cell lung cancer)¿Í ¼Ò¼¼Æ÷Æó¾Ï(small cell lung cancer)·Î ±¸ºÐÀ» Çϴµ¥, ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì Á¾¾ç¼¼Æ÷ÀÇ ¼ºÀåÀÌ ´À¸®°í ¼ö¼úÀû Á¦°Å°¡ Ä¡·áÀÇ ±âº»ÀÌ µÇ°í ¿¹Èĵµ ÁÁÀº ¹Ý¸é, ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì¿¡´Â ¾Ï¼¼Æ÷ÀÇ ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ä¡·áµµ ¹æ»ç¼±Ä¡·á¸¦ ±âº»À¸·Î Çϸ砿¹Èĵµ ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ ºñÇØ¼­ ÁÁÁö°¡ ¸øÇÏ´Ù.
¿µ¹® embryonal carcinoma ÇÑ±Û ¹è¾Æ¾ÏÁ¾
¼³¸í   
  »ý½Ä¼¼Æ÷¿¡¼­ »ý±â´Â ¾ÏÁ¾ÀÇ Çϳª·Î ´ëºÎºÐ °íȯ¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô´Â Á¾°Ýµ¿¿¡¼­µµ ¹ß»ýÇÑ´Ù. 40~50´ëÀÇ ³²¼º¿¡°Ô ¸¹À¸³ª, À̺¸´Ù ³·Àº ¿¬·ÉÃþ¿¡¼­µµ ³ªÅ¸³­´Ù. À°¾ÈÀûÀ¸·Î´Â È¸¹é»öÀÇ ºÐ¿±À» º¸À̴ µ¢¾î¸®¸¦ Çü¼ºÇϸç, °íȯ ¾Ç¼º Á¾¾ç Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ´Ù. Ä¡·áÀÇ ¿øÄ¢Àº °¡±ÞÀû ½Å¼ÓÇϰԠ¿ø¹ß¼Ò¸¦ ÀýÁ¦ÇÏ°í ¿¹»óµÇ´Â ÀüÀ̺´ÅÍ¿¡ ´ëÇÏ¿© ¹æ»ç¼± Á¶»ç¿ä¹ýÀ» ÇàÇØ¾ß ÇÑ´Ù. Å»ý¾ÏÁ¾ ¹æ»ç¼±¿ä¹ý¿¡ ´ëÇÏ¿© ¸Å¿ì °¨¼ö¼ºÀÌ ³ô±â ¶§¹®¿¡ º´±â°¡ ÃʱâÀ̸é 90% ÀÌ»óÀÇ Ä¡·á°¡ ±â´ëµÈ´Ù. ±×¸®°í È­Çпä¹ýÁ¦¿¡ ÀÇÇØ ±× Ä¡·á¼º°ú°¡ »ó½ÂÇϰí ÀÖ´Ù.
¿µ¹® carcinoma in situ ÇÑ±Û »óÇdz»¾ÏÁ¾
¼³¸í   
  ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí Àִ Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ À־ »óÇǿ͠ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È­¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ Àִ °æ¿ì¸¦ ¸»ÇÑ´Ù.
¿µ¹® carcinoma ÇÑ±Û ¾ÏÁ¾
¼³¸í   
  ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷(-½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í Çϰí, »óÇǸ¦ ÀÌ·ç°í Àִ ¼¼Æ÷¸¦ »óÇǼ¼Æ÷¶ó°í ÇÑ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ÀÇÇÑ ¾Ç¼ºÁ¾¾çÀ» À̸£´Â ¸»ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adenomatoid odontogenic tumor
    »ùÁ¾¸ð¾çÄ¡¿ø¼ºÁ¾¾ç
  • adenomatoid tumor
    »ùÁ¾¸ð¾çÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • collision tumor
    Ãæµ¹Á¾¾ç
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • cystic tumor
    ³¶¼ºÁ¾¾ç
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • Ewing¡¯s tumor
    À¯À×Á¾¾ç
  • embryonal tumor
    ¹è¾Æ¼ºÁ¾¾ç
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç, ³»¹è¿±µ¿Á¾¾ç
  • fecal tumor
    ´ëº¯µ¢ÀÌ, ºÐÁ¾(ÝÐðþ)
  • gastrointestinal autonomic nerve tumor
    À§Ã¢ÀÚÀÚÀ²½Å°æÁ¾¾ç, À§Àå°üÀÚÀ²½Å°æÁ¾¾ç
  • gastrointestinal stromal tumor
    À§Ã¢ÀÚ±âÁúÁ¾¾ç, À§Àå°ü±âÁúÁ¾¾ç
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç
  • Gleason tumor grade
    ±Û¸®½¼Á¾¾çµî±Þ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • sex cord-stromal tumor tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • anaplastic carcinoma
    ¿ªÇü¼º¾ÏÁ¾
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
  • invasive carcinoma
    ħ½À¾ÏÁ¾
  • medullary carcinoma
    ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • neuroendocrine carcinoma
    ½Å°æ³»ºÐºñ¾ÏÁ¾
  • occult breast carcinoma
    ÀáÀçÀ¯¹æ¾ÏÁ¾
  • papillary carcinoma
    À¯µÎ¾ÏÁ¾
  • papillary thyroid carcinoma
    À¯µÎ°©»ó»ù¾ÏÁ¾
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acinar carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • adenocystic carcinoma
    (¢¡adenoid cystic carcinoma) »ù³¶¾ÏÁ¾
  • adenoid cystic carcinoma
    »ù³¶¾ÏÁ¾
  • adenoma-carcinoma sequence
    »ùÁ¾¾ÏÁ¾¼ø¼­
  • adnexal carcinoma
    ºÎ¼Ó±â°ü¾ÏÁ¾
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¶¡»ù¾ÏÁ¾
  • arsenical carcinoma
    ºñ¼Ò¾ÏÁ¾
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • bronchioloalveolar carcinoma
    ¼¼±â°üÁöÆóÆ÷¾ÏÁ¾, ¼¼±â°üÁö²Ê¸®¾ÏÁ¾
  • bronchogenic carcinoma
    ±â°üÁöÀ¯·¡¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Ehrlich reaction
    ¿¡¸£¸®È÷ ¹ÝÀÀ
  • Meibomian gland carcinoma
    ¸¶À̺½¼± ¾Ï(Á¾)
  • Merkel cell carcinoma
    ¸Þ¸£Ä̼¼Æ÷ ¾Ï(Á¾)
  • acinar carcinoma
    ¼±¹æ¾ÏÁ¾(¼±¹æ¾ÏÁ¾).
  • acinic cell carcinoma
    ¼±¹æ¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenocystic carcinoma
    ¼±³¶Á¾¼º¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾(àÍåÆÒ¥àõäßðþ)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adenoma-carcinoma sequence
    ¼±Á¾-¾ÏÁ¾ ¿¬¼â(àÍðþ-äßðþ ææáð)
  • adnexal carcinoma
    ºÎ¼Ó±â(ݾáÕÐï) ¾Ï
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¼±(~ àÍ) ¾Ï(Á¾)(äß(ðþ))
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arsenical carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ¾Ï(Á¾)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • superior sulcus tumor(carcinoma)=pancoast tumor
    »ó±¸¾ÏÁ¾
  • brain tumor =cerebral tumor
    ½Å ¿Ü ³úÁ¾¾ç(ÒàðþåË).
  • trichilemmal tumor => pilar tumor
  • tumor albus =white tumor ³ª
    ¹éÁ¾(ÛÜðþ)
  • acinar carcinoma
    ¼±¹æ¾ÏÁ¾(¼±¹æ¾ÏÁ¾).
  • acinic cell carcinoma
    ¼±¹æ¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenocystic carcinoma
    ¼±³¶Á¾¼º¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾(àÍåÆÒ¥àõäßðþ)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adenoma-carcinoma sequence
    ¼±Á¾-¾ÏÁ¾ ¿¬¼â(àÍðþ-äßðþ ææáð)
  • adnexal carcinoma
    ºÎ¼Ó±â(ݾáÕÐï) ¾Ï
  • adrenal carcinoma
    ºÎ½Å¾ÏÁ¾
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Deficiency (Monstrous tumor)
    °áÇÌ (±«¹°Á¾)
    [¿¾ ¿ë¾î] °áÇÌ
  • Monstrous tumor
    ±«¹°Á¾
    [¿¾ ¿ë¾î] ±«¹°Á¾
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Ehrlich ascites tumor
    ¿¡¸¦¸®È÷ º¹¼öÁ¾(ÜÙâ©ðþ)
  • carcinoma
    ¾ÏÁ¾(äßðú)
  • Ehrlich reaction
    ¿¡¸¦¸®È÷ ¹ÝÀÀ(Úãëë)
  • Ehrlich's reagent
    ¿¡¸¦¸®È÷ ½Ã¾à(ãËå·)
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • ectopic tumor
    ÀÌ¼Ò Á¾¾ç(ì¶á¶ðþåË)
  • primary tumor
    ¿ø¹ß¼º Á¾¾ç(ê«Û¡àõðþåË)
  • tumor angiogenesis facotr
    Á¾¾ç Ç÷°üÇü¼ºÀÎÀÚ(ðþåËúìηû¡à÷ì×í­)
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
  • tumor initiator
    Á¾¾ç °³½ÃÀÚ(ðþåËËÒã·í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • tumor progression
    Á¾¾çÁøÇà(ðþåËòäú¼)
  • tumor promoter
    Á¾¾çÃËÁøÀÚ(ðþåËõµòäí­)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • tumor virus
    Á¾¾ç(ðþåË)¹ÙÀÌ·¯½º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾
  • alveolar cell carcinoma
    ÆóÆ÷¼¼Æ÷¾ÏÁ¾
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾, µ¿¼Ò³»¾ÏÁ¾, ÀνÃÅõ¾ÏÁ¾
  • epidermoid carcinoma
    Ç¥ÇǾç¾ÏÁ¾
  • intraductal carcinoma
    °ü³»¾ÏÁ¾
  • invasive carcinoma
    ħ½À¼º¾ÏÁ¾
  • islet cell carcinoma
    µµ¼¼Æ÷¾ÏÁ¾
  • medullary carcinoma
    ¼öÁú¼º¾ÏÁ¾
  • mucinous carcinoma
    Á¡¾×¾ÏÁ¾
  • mucoepidermoid carcinoma
    Á¡¾×Ç¥ÇǾç¾ÏÁ¾
  • mucosal carcinoma
    Á¡¸·¾ÏÁ¾
  • pancreatic carcinoma
    ÃéÀå¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
EAC Ehrlich ascites carcinoma; electroacupuncture; epithelioma adenoides cysticum; erythema annulare cen...
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
EAT Eating Attitudes Test; Ehrlich ascites tumor; electro-aerosol therapy; epidermolysis acuta toxica; e...
EATC Ehrlich ascites tumor cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
EAC Ehrlich Ascites Carcinoma
EAT Ehrlich Ascites Tumor
EA Ehrlich Ascites
EATC Ehrlich Ascites tumour cells
TCC Transitional Cell Carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Ehrlich`s side chain theory
    ¿¡¸¦¸®È÷ÀÇ Ãø¼â¼³
    Ç×ü »ý»ê ±âÀü¿¡ ´ëÇÏ¿© Á¦¾ÈµÈ °¡¼³ÀÇ Çϳª. ¸ðµç ü ¼¼Æ÷ Ç¥¸é¿¡´Â Ãø¼â¶ó°í ÇÏ´Â ¼ö¿ëü°¡ ÀÖ°í, À̰Ϳ¡ ´ëÀÀÇÏ´Â Ç׿øÀÌ °áÇÕÇϸé Ȱ¼ºÈ­ µÇ°í, Ãø¼â°¡ °úÀ× »ý»êµÇ¾î Ç×ü·Î¼­ Ç÷·ù ¼Ó¿¡ ¹æÃâµÈ´Ù°í ÇÏ´Â »ý°¢. Ç×ü »ý»êÀÇ ¼±Åü³ÀÇ ÃÖÃÊÀÇ °ÍÀÌ´Ù.
  • Heinz-Ehrlich body
    ÇÏÀÎÁî-¿¡¸¦¸®È÷¼Òü
    Ç÷»ö¼ÒÀÇ »êÈ­ Àå¾Ö¿Í ±× ħÀüÀ¸·Î »ý±ä ±¸»óÀÇ ºÀÀÔü·Î¼­, ¾î¶² Á¾·ùÀÇ ºñÁ¤»ó Ç÷»ö¼Ò ¹× È¿¼Ò °áÇÌ ÀûÇ÷±¸°¡ Á¸ÀçÇÒ ¶§ º¼ ¼ö ÀÖ´Ù. Ç÷¾× µµ¸» Ç¥º»¿¡¼­´Â ±¼Àý¼ºÀ̸ç Romanowsky ¿°»ö¹ýÀ¸·Î´Â ¿°»öµÇÁö ¾Ê°í, ÃÊ»ýü ¿°»ö¹ýÀ¸·Î ¿°»öµÈ´Ù.
  • acinar carcinoma
    ¼±¹æ ¾ÏÁ¾
    ÃéÀå ¾ÏÁ¾ Áß µå¹°°Ô ¾ÏÁ¾ÀÌ ¼±¹æ¼¼Æ÷¿¡¼­ ¹ß»ýÇÏ´Â °Í. À̵é Á¾¾çÀº Á¾¾ç ¼¼Æ÷µéÀÌ ¶×¶×ÇÏ°í ´Ù°¢ÇüÀ̸ç È£»ê¼º ¼Ò°ßÀ» º¸ÀÌ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù.
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • acinous carcinoma
    ¼±¹æ»ó ¾ÏÁ¾
    ¼¼Æ÷°¡ ¼±¹æ ±¸Á¶¸¦ Çü¼ºÇϵ簡 ȤÀº ¼¼Æ÷°¡ È®½ÇÈ÷ ¼±¹æ¼¼Æ÷¿¡¼­ »ý°Ü³µ´Ù°í »ý°¢µÇ´Â ¾Ç¼º Á¾¾ç.
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç ±âÀú¼¼Æ÷¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenoma-carcinoma sequence
    ¼±Á¾-¾ÏÁ¾ ¿¬¼â
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adnexal carcinoma
    ºÎ¼Ó±â ¾Ï
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • anaplastic carcinoma
    ¿ªÇü¼º ¾ÏÁ¾
    µå¹°°Ô ¹ß»ý. È£¹ß ¿¬·ÉÀº 60-70´ëÀ̰í ÀÎüÀÇ ¾ÏÁß ¾Ç¼ºµµ°¡ ¾ÆÁÖ ³ôÀº ÂÊ¿¡ ¼ÓÇÏ¸ç ¹ÌºÐÈ­ ¾ÏÁ¾À̶ó°í ÇÑ´Ù. ÀÓ»óÀûÀ¸·Î ÀÎÁöµÉ ¶§ °©»ó¼± »Ó ¾Æ´Ï¶ó ÁÖº¯ Á¶Á÷±îÁö ħÅõÇÏ¿© Å« µ¢¾î¸®¸¦ Çü¼ºÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¼Ò ¼¼Æ÷ ¾ÏÁ¾
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
carcinoma, ehrlich tumour A transplantable, poorly differentiated malignant tumour which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
(12 Dec 1998)
tumor 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant.
2. Swelling, one of the cardinal signs of inflammations, morbid enlargement.
Origin: L. Tumere = to swell
(12 May 1997)
tumor marker <investigation, oncology> A substance in the body that usually indicates the presence of cancer.
These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples.
Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH).
They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
(18 Jul 2002)
tumor necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
Paul Ehrlich <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Heinz-Ehrlich body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich Paul, German bacteriologist, immunologist, and Nobel laureate, 1854-1915.
See: Ehrlichia, Ehrlich's anaemia, Ehrlich's inner body, Ehrlich's phenomenon, Ehrlich's postulate, Ehrlich's diazo reagent, Ehrlich's theory, Ehrlich-Turk line. See entries under stain; reaction.
(05 Mar 2000)
Ehrlich, Paul <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Ehrlich reaction The reaction of the indole derivatives with aromatic aldehydes; e.g., tryptophan and p-dimethylaminobenzaldehyde in H2SO4 give a red-violet colour useful in assaying proteins for tryptophan content.
Synonym: Ehrlich reaction.
(05 Mar 2000)
Ehrlich's acid haematoxylin stain <technique> An alum type of haematoxylin stain used as a regressive staining method for nuclei, followed by differentiation to required staining intensity; the solution may be allowed to ripen naturally in sunlight or partially oxidised with sodium iodate.
(05 Mar 2000)
Ehrlich's anaemia <haematology> This form of anaemia occurs when the bone marrow ceases sufficient red and white blood cell production. It may be induced by exposures to high levels of toxic chemicals, radiation and certain drugs.
It is generally unresponsive to specific therapy, often accompanied by granulocytopenia and thrombocytopenia, in which the bone marrow may not necessarily be hypocellular or hypoplastic but fails to produce adequate numbers of peripheral blood elements. The term actually is all inclusive and most probably encompasses several clinical syndromes.
Origin: Gr. Haima = blood
(29 Sep 1997)
Ehrlich's aniline crystal violet stain <technique> A stain for Gram-positive bacteria.
(05 Mar 2000)
Ehrlich's benzaldehyde reaction A test for urobilinogen in the urine, by dissolving 2 g of dimethyl-p-aminobenzaldehyde in 100 ml of 5% hydrochloric acid and adding this reagent to urine; a red colour in the cold indicates the presence of an excessive amount of urobilinogen.
(05 Mar 2000)
Ehrlich's diazo reaction The reaction of diazotised sulfanilic acid with bilirubin to form azobilirubin, which forms the basis of quantitating the amount of bilirubin in biological fluids.
See: van den Bergh's test.
Synonym: Ehrlich's diazo reaction.
(05 Mar 2000)
Ehrlich's diazo reagent Two solutions, one of sodium nitrite, the other of acidified sulfanilic acid, used in bringing about diazotization.
Synonym: Ehrlich's diazo reagent.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Carcinoma, Ehrlich Tumor - »õâ A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
    Synonyms : Ascites Tumor, Ehrlich, Ehrlich Tumor Carcinoma, Tumor, Ehrlich Ascites
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoma
    ¾ÏÁ¾(cancer)n
  • tumor
    Á¾±â
  • tumor
    Á¾Ã¢;ºÎ±â;Á¾±â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á